MK-2870-023: A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer

17054MK-2870-023-NCT06422143OpenMK-2870-023: A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung CancerMK-2870-023NCT06422143IndustrialAdultTreatmentIIIGlobalLungChen, Kevin; Jeon, HyeinMedStar Health and GUMC; Medstar Washington Hospital Center : Leila SounnaThoracic/CNS/H&N/ThyroidOncology GroupMHRI Washington Cancer Institute7150Jennifer LatteriJennifer Latterijennifer.a.latteri@medstar.net13705Leila SounnaLeila SounnaLeila.Sounna@Medstar.net2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>